Cargando…
Multikinase Inhibitor Treatment in Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) therapy. Unfortunately, some thyroid cancer types are resistant to surgical and RAI therapy. Multikinase inhibitors (MKIs) can b...
Autores principales: | Ancker, Ole Vincent, Krüger, Marcus, Wehland, Markus, Infanger, Manfred, Grimm, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982227/ https://www.ncbi.nlm.nih.gov/pubmed/31861373 http://dx.doi.org/10.3390/ijms21010010 |
Ejemplares similares
-
The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
por: Ancker, Ole Vincent, et al.
Publicado: (2017) -
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019) -
Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
por: Kaae, Anne Christine, et al.
Publicado: (2021) -
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018) -
Potential Beneficial Effects of Vitamin D in Coronary Artery Disease
por: Legarth, Christian, et al.
Publicado: (2019)